Hereditary hemochromatosis: Time for targeted screening

Annals of Internal Medicine

Volumn 149, Issue 4, 2008, Pages 270-272

  Phatak, Pradyumna D ^b   Bonkovsky, Herbert L ^c   Kowdley, Kris V ^a  

^a VIRGINIA MASON MEDICAL CENTER   (United States)

^b ROCHESTER GENERAL HOSPITAL   (United States)

^c Carolinas Health Care System   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COST BENEFIT ANALYSIS; EARLY DIAGNOSIS; ENVIRONMENTAL FACTOR; GENE MUTATION; GENETIC DISORDER; GENETIC SCREENING; GENETICS; GENOTYPE; HEALTH CARE COST; HEMOCHROMATOSIS; HIGH RISK POPULATION; HUMAN; IRON DEFICIENCY; IRON OVERLOAD; MORBIDITY; MORTALITY; NEWBORN SCREENING; PHENOTYPE; POINT OF CARE TESTING; PRIORITY JOURNAL; RISK ASSESSMENT; SCREENING; SHORT SURVEY; ARTICLE; ECONOMICS; MUTATION; RISK FACTOR;

HFE PROTEIN, HUMAN; HLA ANTIGEN CLASS 1; MEMBRANE PROTEIN;

COST-BENEFIT ANALYSIS; EARLY DIAGNOSIS; GENETIC SCREENING; GENOTYPE; HEMOCHROMATOSIS; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; MEMBRANE PROTEINS; MUTATION; PHENOTYPE; RISK FACTORS;

EID: 49849106357     PISSN: 00034819     EISSN: None     Source Type: Journal    
DOI: 10.7326/0003-4819-149-4-200808190-00009     Document Type: Short Survey

References (20)

1. Powell LW, Subramaniam VN, Yapp TR. Haemochromatosis in the new millennium. J Hepatol. 2000;32:48-62. [PMID: 10728794]
2. Bacon BR, Powell LW, Adams PC, Kresina TF, Hoofnagle JH. Molecular medicine and hemochromatosis: at the crossroads. Gastroenterology. 1999;116: 193-207. [PMID: 9869618]
3. Niederau C, Stremmel W, Strohmeyer GW. Clinical spectrum and management of haemochromatosis. Baillieres Clin Haematol. 1994;7:881-901. [PMID: 7881158]
4. Niederau C, Fischer R, Pürschel A, Stremmel W, Häussinger D, Strohmeyer G. Long-term survival in patients with hereditary hemochromatosis. Gastroenterology. 1996;110:1107-19. [PMID: 8613000]
5. Feder JN, Gnirke A, Thomas W, Tsuchihashi Z, Ruddy DA, Basava A, et al. A novel MHC class I-like gene is mutated in patients with hereditary haemochromatosis. Nat Genet. 1996;13:399-408. [PMID: 8696333]
6. Phatak PD, Sham RL, Raubertas RF, Dunnigan K, O'Leary MT, Braggins C, et al. Prevalence of hereditary hemochromatosis in 16031 primary care patients. Ann Intern Med. 1998;129:954-61. [PMID: 9867748]
7. Beutler E, Felitti VJ, Koziol JA, Ho NJ, Gelbart T. Penetrance of 845G3A (C282Y) HFE hereditary haemochromatosis mutation in the USA. Lancet. 2002;359:211-8. [PMID: 11812557]
8. Qaseem A, Aranson M, Fitterman N, Snow V, Weiss KB, Owens DK, et al. Clinical Efficacy Assessment Subcommittee of the American College of Physicians. Screening for hereditary hemochromatosis: a clinical practice guideline from the American College of Physicians. Ann Intern Med. 2005;143:517-21. [PMID: 16204164]
9. Whitlock EP, Garlitz BA, Harris EL, Beil TL, Smith PR. Screening for hereditary hemochromatosis: a systematic review for the U.S. Preventive Services Task Force. Ann Intern Med. 2006;145:209-23. [PMID: 16880463]
10. Cadman D, Chambers L, Feldman W, Sackett D. Assessing the effectiveness of community screening programs. JAMA. 1984;251:1580-5. [PMID: 6700057]
11. Adams PC, Barton JC. Haemochromatosis. Lancet. 2007;370:1855-60. [PMID: 18061062]
12. Jacobs EM, Hendriks JC, Marx JJ, van Deursen CT, Kreeftenberg HG, de Vries RA, et al. Morbidity and mortality in first-degree relatives of C282Y homozygous probands with clinically detected haemochromatosis compared with the general population: the HEmochromatosis FAmily Study (HEFAS). Neth J Med. 2007;65:425-33. [PMID: 18079565]
13. Adams P, Reboussin D, Barton J, McClaren C, Eckfeldt J, McClaren G, et al. Hemochromatosis and Iron Overload Screening (HEIRS) Study Research Investigators. Hemochromatosis and iron-overload screening in a racially diverse population. N Engl J Med. 2005;352:1769-78. [PMID: 15858186]
14. Allen KJ, Gurrin LC, Constantine CC, Osborne NJ, Delatycki MB, Nicoll AJ, et al. Iron-overload-related disease in HFE hereditary hemochromatosis. N Engl J Med. 2008;358:221-30. [PMID: 18199861]
15. Hall MA, McEwen JE, Barton JC, Walker AP, Howe EG, Reiss JA, et al. Concerns in a primary care population about genetic discrimination by insurers. Genet Med. 2005;7:311-6. [PMID: 15915082]
16. Adams PC, Valberg LS. Screening blood donors for hereditary hemochromatosis: decision analysis model comparing genotyping to phenotyping. Am J Gastroenterol. 1999;94:1593-600. [PMID: 10364030]
17. Gagné G, Reinharz D, Laflamme N, Adams PC, Rousseau F. Hereditary hemochromatosis screening: effect of mutation penetrance and prevalence on cost-effectiveness of testing algorithms. Clin Genet. 2007;71:46-58. [PMID: 17204047]
18. Robson KJH, Merryweather-Clarke AT, Pointon JJ, Shearman JD, Halsall DJ, Kelly A, et al. Diagnosis and management of haemochromatosis since the discovery of the HFE gene: a European experience. Br J Haematol. 2000;108:31-9. [PMID: 10651721]
19. Carella M, D'Ambrosio L, Totaro A, Grifa A, Valentino MA, Piperno A, et al. Mutation analysis of the HLA-H gene in Italian hemochromatosis patients. Am J Hum Genet. 1997;60:828-32. [PMID: 9106528]
20. Camaschella C, Roetto A, Calì A, De Gobbi M, Garozzo G, Carella M, et al. The gene TFR2 is mutated in a new type of haemochromatosis mapping to 7q22. Nat Genet. 2000;25:14-5. [PMID: 10802645]